PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2019

WALTHAM, Mass.--(BUSINESS WIRE)--January 27, 2020--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended December 29, 2019.

Fourth Quarter 2019
The Company reported GAAP earnings per share from continuing operations of $0.58, as compared to GAAP earnings per share from continuing operations of $0.64 in the fourth quarter of 2018. GAAP revenue for the quarter was $805.5 million, as compared to $756.3 million in the fourth quarter of 2018. GAAP operating income from continuing operations for the quarter was $138.2 million, as compared to $115.7 million for the same period a year ago. GAAP operating profit margin was 17.2% as a percentage of revenue, as compared to 15.3% in the fourth quarter of 2018.

Adjusted earnings per share from continuing operations for the quarter was $1.35, as compared to $1.18 in the fourth quarter of 2018. Adjusted revenue for the quarter was $805.7 million, as compared to $756.5 million in the fourth quarter of 2018. Adjusted operating income from continuing operations for the quarter was $192.3 million, as compared to $164.3 million for the same period a year ago. Adjusted operating profit margin was 23.9% as a percentage of adjusted revenue, as compared to 21.7% in the fourth quarter of 2018.

Full Year 2019
The Company reported GAAP earnings per share from continuing operations of $2.04, as compared to GAAP earnings per share from continuing operations of $2.13 in 2018. GAAP revenue for the year was $2.88 billion, as compared to $2.78 billion in 2018. GAAP operating income from continuing operations for the year was $362.0 million, as compared to $323.9 million in 2018. GAAP operating profit margin was 12.6% as a percentage of revenue, as compared to 11.7% in 2018.

Adjusted earnings per share from continuing operations for the year was $4.10, as compared to $3.61 in 2018. Adjusted revenue for the year was $2.88 billion, as compared to $2.78 billion in 2018. Adjusted operating income from continuing operations for the year was $596.0 million, as compared to $527.1 million in 2018. Adjusted operating profit margin was 20.7% as a percentage of adjusted revenue, as compared to 19.0% in 2018.

Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

“We are pleased with our strong finish to 2019. The rapid transformation we made as an organization over the past few years and in particular 2019 has put us in an excellent position to accelerate profitable growth and advance outcomes around the world in 2020 and beyond,” said Prahlad Singh, president and chief executive officer of PerkinElmer.

Financial Overview by Reporting Segment for the Fourth Quarter and Full Year 2019

Discovery & Analytical Solutions

• Fourth quarter 2019 revenue was $496.5 million, as compared to $459.9 million for the fourth quarter of 2018. Reported revenue increased 8% and organic revenue increased 5% as compared to the fourth quarter of 2018. Full year 2019 revenue was $1.75 billion, as compared to $1.69 billion in 2018. Full year reported and organic revenue increased 3%.

• Fourth quarter 2019 operating income from continuing operations was $91.4 million, as compared to $81.2 million for the comparable prior period. Full year 2019 operating income was $238.3 million, as compared to $230.5 million in 2018.

• Fourth quarter 2019 adjusted operating income was $116.0 million, as compared to $92.7 million for the fourth quarter of 2018. Full year 2019 adjusted operating income was $338.0 million, as compared to $295.0 million in 2018.

Diagnostics

• Fourth quarter 2019 revenue was $309.0 million, as compared to $296.5 million for the fourth quarter of 2018. Reported revenue increased 4% and organic revenue increased 5% as compared to the fourth quarter of 2018. Full year 2019 revenue was $1.14 billion, as compared to $1.08 billion in 2018. Full year revenue increased 5% and organic revenue increased 7%.

• Fourth quarter 2019 operating income from continuing operations was $61.1 million, as compared to $48.6 million for the comparable prior period. Full year 2019 operating income was $189.3 million, as compared to $153.2 million in 2018.

• Fourth quarter 2019 adjusted operating income was $90.6 million, as compared to $85.8 million for the fourth quarter of 2018. Full year 2019 adjusted operating income was $316.0 million, as compared to $291.9 million in 2018.

Initiates Financial Guidance: Full-Year and First Quarter 2020

For the full year 2020, the Company forecasts GAAP revenue of $3.05 billion to $3.09 billion. GAAP earnings per share from continuing operations in a range of $2.89-$2.99 and, on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share of $4.50-$4.60.

For the first quarter of 2020, the Company forecasts GAAP revenue of $700 million. GAAP earnings per share from continuing operations of $0.33 and, on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share of $0.70.

Conference Call Information

The Company will discuss its fourth quarter and full year 2019 results and its outlook for business trends in a conference call on January 27, 2020 at 5:00 p.m. Eastern Time. To access the call, please dial (720) 405-2250 prior to the scheduled conference call time and provide the access code 6497348.

A live audio webcast of the call will be available on the Investors section of the Company’s Web site, www.perkinelmer.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Company’s Web site for a two-week period beginning approximately two hours after the call.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems, or cybercrime; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) the United Kingdom’s pending withdrawal from the European Union; (21) our ability to realize the full value of our intangible assets; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.9 billion in 2019, has about 13,000 employees serving customers in more than 190 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
			Three Months Ended										Twelve Months Ended
(In thousands, except per share data)			December 29, 2019					December 30, 2018					December 29, 2019						December 30, 2018
Revenue			$	805,496				$	756,349				$	2,883,673					$	2,777,996
Cost of revenue				407,315					380,099					1,487,618						1,437,057
Selling, general and administrative expenses				210,737					210,539					815,318						811,913
Research and development expenses				47,636					51,970					189,336						193,998
Restructuring and other, net				1,560					(1,942	)				29,428						11,144
Operating income from continuing operations				138,248					115,683					361,973						323,884
Interest income				(570	)				(387	)				(1,495	)					(1,141	)
Interest expense				14,421					16,231					63,627						66,976
Loss (gain) on disposition of businesses and assets, net				-					187					2,469						(12,844	)
Debt extinguishment costs				32,070					-					32,541						-
Other (income) expense, net				27,031					20,223					27,689						13,210
Income from continuing operations, before income taxes				65,296					79,429					237,142						257,683
Provision for income taxes				747					8,107					9,389						20,208
Income from continuing operations				64,549					71,322					227,753						237,475
Loss on disposition of discontinued operations, before income taxes				-					-					-						(859	)
Provision for (benefit from) income taxes on discontinued operations and dispositions				48					30					195						(1,311	)
(Loss) gain from discontinued operations and dispositions				(48	)				(30	)				(195	)					452
Net income			$	64,501				$	71,292				$	227,558					$	237,927
Diluted earnings per share:
Income from continuing operations			$	0.58				$	0.64				$	2.04					$	2.13
(Loss) gain from discontinued operations and dispositions				(0.00	)				(0.00	)				(0.00	)					0.00
Net income			$	0.58				$	0.64				$	2.04					$	2.13
Weighted average diluted shares of common stock outstanding				111,625					111,609					111,501						111,534
ABOVE PREPARED IN ACCORDANCE WITH GAAP
Additional Supplemental Information (1):
(per share, continuing operations)
GAAP EPS from continuing operations				0.58					0.64					2.04						2.13
Amortization of intangible assets				0.39					0.32					1.47						1.22
Debt extinguishment costs				0.29					-					0.29						-
Purchase accounting adjustments				0.07					0.05					0.24						0.31
Acquisition and divestiture-related costs				0.01					0.09					0.06						0.14
Change in fair value of financial securities				(0.03	)				-					(0.03	)					-
Acceleration of executive compensation				-					-					0.07						-
Significant litigation matters				0.01					0.00					0.02						0.05
Disposition of businesses and assets, net				-					0.00					0.02						(0.12	)
Mark to market on postretirement benefits				0.28					0.19					0.28						0.19
Restructuring and other, net				0.01					(0.02	)				0.26						0.10
Tax on above items				(0.25	)				(0.12	)				(0.65	)					(0.40	)
Impact of tax act				-					0.03					0.02						(0.02	)
Adjusted EPS				1.35					1.18					4.10						3.61
(1) amounts may not sum due to rounding

PerkinElmer, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
						Three Months Ended										Twelve Months Ended
(In thousands, except percentages)						December 29, 2019					December 30, 2018					December 29, 2019					December 30, 2018
DAS		Reported revenue			$	496,457				$	459,892				$	1,746,161				$	1,693,211
		Reported operating income from continued operations				91,368					81,238					238,331					230,481
		OP%				18.4	%				17.7	%				13.6	%				13.6	%
		Amortization of intangible assets				15,793					11,553					52,898					46,120
		Purchase accounting adjustments				8,377					308					20,857					409
		Acquisition and divestiture-related costs				375					921					1,778					2,680
		Significant litigation matters				569					297					2,189					5,347
		Restructuring and other, net				(469	)				(1,606	)				21,958					9,960
		Adjusted operating income				116,013					92,711					338,011					294,997
		Adjusted OP%				23.4	%				20.2	%				19.4	%				17.4	%
Diagnostics		Reported revenue				309,039					296,457					1,137,512					1,084,785
		Purchase accounting adjustments				194					190					770					752
		Adjusted Revenue				309,233					296,647					1,138,282					1,085,537
		Reported operating income from continued operations				61,146					48,611					189,330					153,196
		OP%				19.8	%				16.4	%				16.6	%				14.1	%
		Amortization of intangible assets				27,335					23,703					111,429					89,815
		Purchase accounting adjustments				(369	)				4,859					5,412					34,376
		Acquisition and divestiture-related costs				332					8,955					2,210					13,131
		Significant litigation matters				106					-					106					193
		Restructuring and other, net				2,029					(336	)				7,470					1,184
		Adjusted operating income				90,579					85,792					315,957					291,895
		Adjusted OP%				29.3	%				28.9	%				27.8	%				26.9	%
Corporate		Reported operating loss				(14,266	)				(14,166	)				(65,688	)				(59,793	)
		Acceleration of executive compensation				-					-					7,721					-
		Adjusted operating loss				(14,266	)				(14,166	)				(57,967	)				(59,793	)
Continuing Operations		Reported revenue			$	805,496				$	756,349				$	2,883,673				$	2,777,996
		Purchase accounting adjustments				194					190					770					752
		Adjusted Revenue				805,690					756,539					2,884,443					2,778,748
		Reported operating income from continued operations				138,248					115,683					361,973					323,884
		OP%				17.2	%				15.3	%				12.6	%				11.7	%
		Amortization of intangible assets				43,128					35,256					164,327					135,935
		Purchase accounting adjustments				8,008					5,167					26,269					34,785
		Acquisition and divestiture-related costs				707					9,876					3,988					15,811
		Acceleration of executive compensation				-					-					7,721					-
		Significant litigation matters				675					297					2,295					5,540
		Restructuring and other, net				1,560					(1,942	)				29,428					11,144
		Adjusted operating income			$	192,326				$	164,337				$	596,001				$	527,099
		Adjusted OP%				23.9	%				21.7	%				20.7	%				19.0	%
REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)			December 29, 2019					December 30, 2018
Current assets:
Cash and cash equivalents			$	191,877				$	163,111
Accounts receivable, net				725,184					632,669
Inventories, net				356,937					338,347
Other current assets				100,523					100,507
Total current assets				1,374,521					1,234,634
Property, plant and equipment:
At cost				701,580					680,183
Accumulated depreciation				(383,357	)				(361,593	)
Property, plant and equipment, net				318,223					318,590
Operating lease right-of-use assets				167,276					-
Intangible assets, net				1,283,286					1,199,667
Goodwill				3,111,227					2,952,608
Other assets, net				290,032					270,023
Total assets			$	6,544,565				$	5,975,522
Current liabilities:
Current portion of long-term debt			$	9,974				$	14,856
Accounts payable				235,855					220,949
Short-term accrued restructuring and other				11,559					4,834
Accrued expenses and other current liabilities				509,333					528,827
Current liabilities of discontinued operations				2,112					2,165
Total current liabilities				768,833					771,631
Long-term debt				2,064,041					1,876,624
Long-term liabilities				751,468					742,312
Operating lease liabilities				146,399					-
Total liabilities				3,730,741					3,390,567
Total stockholders' equity				2,813,824					2,584,955
Total liabilities and stockholders' equity			$	6,544,565				$	5,975,522
PREPARED IN ACCORDANCE WITH GAAP

PerkinElmer, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
			Three Months Ended										Twelve Months Ended
			December 29, 2019					December 30, 2018					December 29, 2019					December 30, 2018
			(In thousands)										(In thousands)
Operating activities:
Net income			$	64,501				$	71,292				$	227,558				$	237,927
Loss (gain) from discontinued operations and dispositions, net of income taxes				48					30					195					(452	)
Income from continuing operations				64,549					71,322					227,753					237,475
Adjustments to reconcile income from continuing operations
to net cash provided by continuing operations:
Stock-based compensation				6,409					5,492					31,514					28,767
Restructuring and other, net				1,560					(1,942	)				29,428					11,144
Depreciation and amortization				56,908					47,202					214,025					180,588
Pension and other postretirement expenses				26,107					11,915					26,107					11,915
Change in fair value of contingent consideration				(518	)				3,835					3,881					14,639
Amortization of deferred debt financing costs and accretion of discounts				1,068					887					3,846					3,341
Loss (gain) on disposition of businesses and assets, net				-					187					2,469					(12,844	)
Gain on sale of investments, net				-					-					-					(557	)
Change in fair value of financial securities				(3,249	)				-					(3,249	)				-
Debt extinguishment costs				32,070					-					32,541					-
Amortization of acquired inventory revaluation				8,332					1,112					21,590					19,272
Deferred taxes				(52,678	)				(51,103	)				(52,678	)				(51,103	)
Contingencies and non-cash tax matters				(424	)				(671	)				(424	)				(671	)
Changes in assets and liabilities which provided (used) cash, excluding
effects from companies acquired:
Accounts receivable, net				(78,498	)				(81,842	)				(100,630	)				(94,512	)
Inventories				38,761					11,129					(9,607	)				(30,183	)
Accounts payable				41,394					45,487					7,351					8,900
Accrued expenses and other				73,419					96,409					(70,448	)				(14,933	)
Net cash provided by operating activities of continuing operations				215,210					159,419					363,469					311,238
Net cash used in operating activities of discontinued operations				-					-					-					(200	)
Net cash provided by operating activities				215,210					159,419					363,469					311,038
Investing activities:
Capital expenditures				(23,249	)				(32,810	)				(76,331	)				(93,253	)
Purchases of investments				(1,000	)				(1,519	)				(6,387	)				(7,019	)
Purchases of licenses				-					-					(5,000	)				-
Proceeds from surrender of life insurance policies				-					-					-					72
Proceeds from disposition of businesses and assets				-					-					550					38,027
Payment of acquisitions, net of cash and cash equivalents acquired				(147,785	)				(53,629	)				(400,405	)				(97,686	)
Net cash used in investing activities of continuing operations				(172,034	)				(87,958	)				(487,573	)				(159,859	)
Net cash provided by investing activities of discontinued operations				-					-					-					-
Net cash used in investing activities				(172,034	)				(87,958	)				(487,573	)				(159,859	)
Financing Activities:
Payments on borrowings				(273,000	)				(245,000	)				(1,692,489	)				(1,264,000	)
Proceeds from borrowings				565,000					252,000					1,599,416					857,000
Payments of senior debt				(530,276	)				-					(530,276	)				-
Proceeds from sale of senior debt				-					-					847,195					369,340
Payments of debt financing costs				(1,854	)				-					(9,879	)				(2,634	)
Settlement of cash flow hedges				307					(3,847	)				(1,280	)				(34,132	)
Net payments on other credit facilities				(3,911	)				(5,512	)				(14,975	)				(28,383	)
Payments for acquisition-related contingent consideration				(1,742	)				-					(29,942	)				(12,800	)
Proceeds from issuance of common stock under stock plans				2,169					5,348					19,732					24,833
Purchases of common stock				(112	)				(52,471	)				(6,313	)				(57,445	)
Dividends paid				(7,777	)				(7,787	)				(31,059	)				(31,009	)
Net cash (used in) provided by financing activities of continuing operations				(251,196	)				(57,269	)				150,130					(179,230	)
Net cash used in financing activities of discontinued operations				-					-					-					-
Net cash (used in) provided by financing activities				(251,196	)				(57,269	)				150,130					(179,230	)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash				3,937					(594	)				(447	)				(8,004	)
Net (decrease) increase in cash, cash equivalents, and restricted cash				(204,083	)				13,598					25,579					(36,055	)
Cash, cash equivalents, and restricted cash at beginning of period				395,977					152,717					166,315					202,370
Cash, cash equivalents, and restricted cash at end of period			$	191,894				$	166,315				$	191,894				$	166,315
Supplemental disclosure of cash flow information:
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:
Cash and cash equivalents			$	191,877				$	163,111					191,877				$	163,111
Restricted cash included in other current assets				17					3,204					17					3,204
Total cash, cash equivalents and restricted cash			$	191,894				$	166,315				$	191,894				$	166,315
PREPARED IN ACCORDANCE WITH GAAP

PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
(In millions, except per share data and percentages)			PKI
			Three Months Ended
			December 29, 2019									December 30, 2018
Adjusted revenue:
Revenue			$	805.5								$	756.3
Purchase accounting adjustments				0.2									0.2
Adjusted revenue			$	805.7								$	756.5
Adjusted gross margin:
Gross margin			$	398.2				49.4	%			$	376.3				49.7	%
Amortization of intangible assets				15.8				2.0	%				11.4				1.5	%
Purchase accounting adjustments				8.5				1.1	%				1.3				0.2	%
Adjusted gross margin			$	422.5				52.4	%			$	389.0				51.4	%
Adjusted SG&A:
SG&A			$	210.7				26.2	%			$	210.5				27.8	%
Amortization of intangible assets				(27.4	)			-3.4	%				(19.8	)			-2.6	%
Purchase accounting adjustments				0.5				0.1	%				(3.9	)			-0.5	%
Acquisition and divestiture-related expenses				(0.7	)			-0.1	%				(9.9	)			-1.3	%
Significant litigation matters				(0.7	)			-0.1	%				(0.3	)			0.0	%
Adjusted SG&A			$	182.5				22.7	%			$	176.7				23.4	%
Adjusted R&D:
R&D			$	47.6				5.9	%			$	52.0				6.9	%
Amortization of intangible assets				-				0.0	%				(4.1	)			-0.5	%
Adjusted R&D			$	47.6				5.9	%			$	47.9				6.3	%
Adjusted operating income:
Operating income			$	138.2				17.2	%			$	115.7				15.3	%
Amortization of intangible assets				43.1				5.4	%				35.3				4.7	%
Purchase accounting adjustments				8.0				1.0	%				5.2				0.7	%
Acquisition and divestiture-related expenses				0.7				0.1	%				9.9				1.3	%
Significant litigation matters				0.7				0.1	%				0.3				0.0	%
Restructuring and other, net				1.6				0.2	%				(1.9	)			-0.3	%
Adjusted operating income			$	192.3				23.9	%			$	164.3				21.7	%
			PKI
			Three Months Ended
			December 29, 2019									December 30, 2018
Adjusted EPS:
GAAP EPS			$	0.58								$	0.64
Discontinued operations, net of income taxes				(0.00	)								(0.00	)
GAAP EPS from continuing operations				0.58									0.64
Amortization of intangible assets				0.39									0.32
Debt extinguishment costs				0.29									-
Purchase accounting adjustments				0.07									0.05
Acquisition and divestiture-related expenses				0.01									0.09
Change in fair value of financial securities				(0.03	)								-
Significant litigation matters				0.01									0.00
Disposition of businesses and assets, net				-									0.00
Mark to market on postretirement benefits				0.28									0.19
Restructuring and other, net				0.01									(0.02	)
Tax on above items				(0.25	)								(0.12	)
Impact of tax act				-									0.03
Adjusted EPS			$	1.35								$	1.18
			DAS
			Three Months Ended
			December 29, 2019									December 30, 2018
Revenue			$	496.5								$	459.9
Adjusted operating income:
Operating income			$	91.4				18.4	%			$	81.2				17.7	%
Amortization of intangible assets				15.8				3.2	%				11.6				2.5	%
Purchase accounting adjustments				8.4				1.7	%				0.3				0.1	%
Acquisition and divestiture-related expenses				0.4				0.1	%				0.9				0.2	%
Significant litigation matters				0.6				0.1	%				0.3				0.1	%
Restructuring and other, net				(0.5	)			-0.1	%				(1.6	)			-0.3	%
Adjusted operating income			$	116.0				23.4	%			$	92.7				20.2	%
			Diagnostics
			Three Months Ended
			December 29, 2019									December 30, 2018
Adjusted revenue:
Revenue			$	309.0								$	296.5
Purchase accounting adjustments				0.2									0.2
Adjusted revenue			$	309.2								$	296.6
Adjusted operating income:
Operating income			$	61.1				19.8	%			$	48.6				16.4	%
Amortization of intangible assets				27.3				8.8	%				23.7				8.0	%
Purchase accounting adjustments				(0.4	)			-0.1	%				4.9				1.6	%
Acquisition and divestiture-related expenses				0.3				0.1	%				9.0				3.0	%
Significant litigation matters				0.1				0.0	%				-				0.0	%
Restructuring and other, net				2.0				0.7	%				(0.3	)			-0.1	%
Adjusted operating income			$	90.6				29.3	%			$	85.8				28.9	%
(1) amounts may not sum due to rounding

PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
(In millions, except per share data and percentages)			PKI
			Twelve Months Ended
			December 29, 2019									December 30, 2018
Adjusted revenue:
Revenue			$	2,883.7								$	2,778.0
Purchase accounting adjustments				0.8									0.8
Adjusted revenue			$	2,884.4								$	2,778.7
Adjusted gross margin:
Gross margin			$	1,396.1				48.4	%			$	1,340.9				48.3	%
Amortization of intangible assets				61.4				2.1	%				46.2				1.7	%
Purchase accounting adjustments				22.4				0.8	%				20.1				0.7	%
Adjusted gross margin			$	1,479.8				51.3	%			$	1,407.2				50.6	%
Adjusted SG&A:
SG&A			$	815.3				28.3	%			$	811.9				29.2	%
Amortization of intangible assets				(103.0	)			-3.6	%				(81.8	)			-2.9	%
Purchase accounting adjustments				(3.9	)			-0.1	%				(14.7	)			-0.5	%
Acquisition and divestiture-related expenses				(4.0	)			-0.1	%				(15.8	)			-0.6	%
Acceleration of executive compensation				(7.7	)			-0.3	%				-				0.0	%
Significant litigation matters				(2.3	)			-0.1	%				(5.5	)			-0.2	%
Adjusted SG&A			$	694.5				24.1	%			$	694.1				25.0